BioSpace News Archive

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today it has completed enrollment in its first-in-human study evaluating the company’s Amplifi™ Vein Dilation System.

ZandCell, a biotech company with a proven track record in immunotherapies and COVID-19 diagnostics is announcing that it wants to manufacture the Russian vaccines for worldwide distribution.

LENSAR, Inc., a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, announced that the Company’s second quarter 2021 financial results will be released before market open on Thursday, August 5, 2021.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of market.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront.

PolarityTE, Inc. announced that it will report results for the quarter ended June 30, 2021 by press release on Thursday, August 12, 2021 at approximately 4:00 p.m. Eastern Time.

Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

Mycovia Pharmaceuticals, Inc. (Mycovia), today announced that data from its Phase 3, randomized, double-blind, placebo-controlled VIOLET studies to measure the efficacy and safety of oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC) will be presented at the 2021 Virtual Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG).

Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), today announced that it has dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (wet AMD).